glp 1 fda compounding GLP-1 Compounding: When Innovation May Mean Liability Have patients been harmed by
Description
"Food noise" is the buzz in the battle against obesity

Summary SGLT2-i exert more consistent BP-lowering effects than GLP-1RA, largely due to their diuretic-like action

**Modigy **: Modeller Prodigy , ($K_d$)

Expert UK guidance on Ozempic and light-headedness.

The global incretin-based drugs market was valued at USD 39.4 billion in 2025 and is projected to grow from USD 41.6 billion in 2026 to USD 72.6 billion by 2035, expanding at a CAGR of 6.4% between 2026 and 2035, driven by the rising prevalence of type 2 diabetes mellitus.
At this risk of this newsletter getting a bit long, I wanted to share a little bit about our recent travels